Industrial - Pollution & Treatment Controls
Compare Stocks
5 / 10Stock Comparison
VLTO vs WAT vs DHR vs FELE vs TMO
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Diagnostics & Research
Medical - Diagnostics & Research
Industrial - Machinery
Medical - Diagnostics & Research
VLTO vs WAT vs DHR vs FELE vs TMO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Industrial - Pollution & Treatment Controls | Medical - Diagnostics & Research | Medical - Diagnostics & Research | Industrial - Machinery | Medical - Diagnostics & Research |
| Market Cap | $21.64B | $23.15B | $121.14B | $4.39B | $172.80B |
| Revenue (TTM) | $5.59B | $3.77B | $24.78B | $2.18B | $45.20B |
| Net Income (TTM) | $969M | $449M | $3.69B | $150M | $6.86B |
| Gross Margin | 59.9% | 55.0% | 60.7% | 35.2% | 39.4% |
| Operating Margin | 23.1% | 17.1% | 21.0% | 12.6% | 17.8% |
| Forward P/E | 20.5x | 24.5x | 20.3x | 21.6x | 18.7x |
| Total Debt | $2.67B | $1.41B | $18.42B | $280M | $40.85B |
| Cash & Equiv. | $2.03B | $588M | $4.62B | $100M | $9.86B |
VLTO vs WAT vs DHR vs FELE vs TMO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Sep 23 | May 26 | Return |
|---|---|---|---|
| Veralto Corporation (VLTO) | 100 | 102.7 | +2.7% |
| Waters Corporation (WAT) | 100 | 129.5 | +29.5% |
| Danaher Corporation (DHR) | 100 | 77.8 | -22.2% |
| Franklin Electric C… (FELE) | 100 | 111.3 | +11.3% |
| Thermo Fisher Scien… (TMO) | 100 | 91.9 | -8.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VLTO vs WAT vs DHR vs FELE vs TMO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VLTO carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 6.0%, EPS growth 12.6%, 3Y rev CAGR 4.2%
- 17.3% margin vs FELE's 6.9%
- Beta 0.61 vs WAT's 1.11
- 12.9% ROA vs DHR's 4.5%, ROIC 25.7% vs 5.9%
WAT ranks third and is worth considering specifically for growth.
- 7.0% revenue growth vs DHR's 2.9%
DHR lags the leaders in this set but could rank higher in a more targeted comparison.
FELE is the #2 pick in this set and the best alternative if income & stability and long-term compounding is your priority.
- Dividend streak 32 yrs, beta 0.89, yield 1.1%
- 229.5% 10Y total return vs TMO's 222.6%
- Lower volatility, beta 0.89, Low D/E 21.1%, current ratio 2.79x
- PEG 2.48 vs DHR's 33.47
Among these 5 stocks, TMO doesn't own a clear edge in any measured category.
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 7.0% revenue growth vs DHR's 2.9% | |
| Value | PEG 2.48 vs 33.47 | |
| Quality / Margins | 17.3% margin vs FELE's 6.9% | |
| Stability / Safety | Beta 0.61 vs WAT's 1.11 | |
| Dividends | 1.1% yield, 32-year raise streak, vs TMO's 0.4%, (1 stock pays no dividend) | |
| Momentum (1Y) | +14.9% vs DHR's -11.4% | |
| Efficiency (ROA) | 12.9% ROA vs DHR's 4.5%, ROIC 25.7% vs 5.9% |
VLTO vs WAT vs DHR vs FELE vs TMO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
VLTO vs WAT vs DHR vs FELE vs TMO — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
FELE leads in 3 of 6 categories
VLTO leads 0 • WAT leads 0 • DHR leads 0 • TMO leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
Evenly matched — VLTO and DHR each lead in 2 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
TMO is the larger business by revenue, generating $45.2B annually — 20.8x FELE's $2.2B. VLTO is the more profitable business, keeping 17.3% of every revenue dollar as net income compared to FELE's 6.9%. On growth, WAT holds the edge at +91.5% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $5.6B | $3.8B | $24.8B | $2.2B | $45.2B |
| EBITDAEarnings before interest/tax | $1.4B | $953M | $7.2B | $322M | $10.5B |
| Net IncomeAfter-tax profit | $969M | $449M | $3.7B | $150M | $6.9B |
| Free Cash FlowCash after capex | $1.0B | $264M | $5.3B | $169M | $6.7B |
| Gross MarginGross profit ÷ Revenue | +59.9% | +55.0% | +60.7% | +35.2% | +39.4% |
| Operating MarginEBIT ÷ Revenue | +23.1% | +17.1% | +21.0% | +12.6% | +17.8% |
| Net MarginNet income ÷ Revenue | +17.3% | +11.9% | +14.9% | +6.9% | +15.2% |
| FCF MarginFCF ÷ Revenue | +18.6% | +7.0% | +21.4% | +7.8% | +14.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | +6.8% | +91.5% | +3.7% | +9.9% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +13.3% | -142.9% | +9.8% | +13.4% | +11.3% |
Valuation Metrics
FELE leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 23.1x trailing earnings, VLTO trades at a 32% valuation discount to DHR's 34.0x P/E. Adjusting for growth (PEG ratio), FELE offers better value at 3.51x vs DHR's 33.47x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $21.6B | $23.1B | $121.1B | $4.4B | $172.8B |
| Enterprise ValueMkt cap + debt − cash | $22.3B | $24.0B | $134.9B | $4.6B | $203.8B |
| Trailing P/EPrice ÷ TTM EPS | 23.10x | 33.00x | 33.96x | 30.57x | 26.21x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.48x | 24.53x | 20.29x | 21.64x | 18.71x |
| PEG RatioP/E ÷ EPS growth rate | — | 6.38x | 33.47x | 3.51x | 12.41x |
| EV / EBITDAEnterprise value multiple | 16.44x | 21.80x | 17.79x | 13.74x | 18.72x |
| Price / SalesMarket cap ÷ Revenue | 3.93x | 7.31x | 4.93x | 2.06x | 3.88x |
| Price / BookPrice ÷ Book value/share | 7.00x | 8.28x | 2.32x | 3.39x | 3.27x |
| Price / FCFMarket cap ÷ FCF | 21.34x | 42.88x | 23.03x | 22.67x | 27.46x |
Profitability & Efficiency
Evenly matched — VLTO and FELE each lead in 4 of 9 comparable metrics.
Profitability & Efficiency
VLTO delivers a 33.4% return on equity — every $100 of shareholder capital generates $33 in annual profit, vs $7 for DHR. FELE carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to VLTO's 0.86x. On the Piotroski fundamental quality scale (0–9), DHR scores 7/9 vs WAT's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +33.4% | +8.0% | +7.1% | +11.4% | +13.2% |
| ROA (TTM)Return on assets | +12.9% | +4.6% | +4.5% | +7.6% | +6.4% |
| ROICReturn on invested capital | +25.7% | +20.3% | +5.9% | +14.7% | +7.5% |
| ROCEReturn on capital employed | +23.7% | +18.5% | +7.0% | +18.1% | +9.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 4 | 7 | 5 | 6 |
| Debt / EquityFinancial leverage | 0.86x | 0.55x | 0.35x | 0.21x | 0.76x |
| Net DebtTotal debt minus cash | $642M | $820M | $13.8B | $181M | $31.0B |
| Cash & Equiv.Liquid assets | $2.0B | $588M | $4.6B | $100M | $9.9B |
| Total DebtShort + long-term debt | $2.7B | $1.4B | $18.4B | $280M | $40.9B |
| Interest CoverageEBIT ÷ Interest expense | 13.96x | 6.72x | 18.13x | 24.75x | 5.89x |
Total Returns (Dividends Reinvested)
FELE leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in FELE five years ago would be worth $12,157 today (with dividends reinvested), compared to $7,681 for DHR. Over the past 12 months, FELE leads with a +14.9% total return vs DHR's -11.4%. The 3-year compound annual growth rate (CAGR) favors WAT at 6.2% vs DHR's -6.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -11.7% | -7.0% | -25.5% | +3.0% | -21.4% |
| 1-Year ReturnPast 12 months | -10.2% | +1.2% | -11.4% | +14.9% | +13.6% |
| 3-Year ReturnCumulative with dividends | +9.1% | +19.8% | -17.6% | +9.4% | -13.4% |
| 5-Year ReturnCumulative with dividends | +9.1% | +11.8% | -23.2% | +21.6% | +1.9% |
| 10-Year ReturnCumulative with dividends | +9.1% | +165.6% | +212.4% | +229.5% | +222.6% |
| CAGR (3Y)Annualised 3-year return | +2.9% | +6.2% | -6.3% | +3.0% | -4.7% |
Risk & Volatility
Evenly matched — VLTO and FELE each lead in 1 of 2 comparable metrics.
Risk & Volatility
VLTO is the less volatile stock with a 0.61 beta — it tends to amplify market swings less than WAT's 1.11 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FELE currently trades 89.1% from its 52-week high vs DHR's 70.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.61x | 1.11x | 0.89x | 0.89x | 1.07x |
| 52-Week HighHighest price in past year | $110.11 | $414.15 | $242.80 | $111.53 | $643.99 |
| 52-Week LowLowest price in past year | $84.99 | $275.05 | $170.74 | $83.42 | $385.46 |
| % of 52W HighCurrent price vs 52-week peak | +78.9% | +85.7% | +70.5% | +89.1% | +72.2% |
| RSI (14)Momentum oscillator 0–100 | 49.2 | 65.2 | 34.6 | 51.4 | 43.9 |
| Avg Volume (50D)Average daily shares traded | 1.7M | 1.0M | 4.2M | 275K | 1.9M |
Analyst Outlook
FELE leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: VLTO as "Hold", WAT as "Hold", DHR as "Buy", FELE as "Hold", TMO as "Buy". Consensus price targets imply 44.3% upside for DHR (target: $247) vs 0.7% for FELE (target: $100). For income investors, FELE offers the higher dividend yield at 1.11% vs TMO's 0.36%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Hold | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | $106.14 | $402.75 | $247.00 | $100.00 | $654.67 |
| # AnalystsCovering analysts | 12 | 34 | 42 | 11 | 42 |
| Dividend YieldAnnual dividend ÷ price | +0.5% | — | +0.7% | +1.1% | +0.4% |
| Dividend StreakConsecutive years of raises | 2 | 1 | 1 | 32 | 8 |
| Dividend / ShareAnnual DPS | $0.44 | — | $1.23 | $1.11 | $1.69 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.1% | +2.5% | +3.8% | +1.7% |
FELE leads in 3 of 6 categories — strongest in Valuation Metrics and Total Returns. 3 categories are tied.
VLTO vs WAT vs DHR vs FELE vs TMO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VLTO or WAT or DHR or FELE or TMO a better buy right now?
For growth investors, Waters Corporation (WAT) is the stronger pick with 7.
0% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). Veralto Corporation (VLTO) offers the better valuation at 23. 1x trailing P/E (20. 5x forward), making it the more compelling value choice. Analysts rate Danaher Corporation (DHR) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VLTO or WAT or DHR or FELE or TMO?
On trailing P/E, Veralto Corporation (VLTO) is the cheapest at 23.
1x versus Danaher Corporation at 34. 0x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 18. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Franklin Electric Co. , Inc. wins at 2. 48x versus Danaher Corporation's 33. 47x.
03Which is the better long-term investment — VLTO or WAT or DHR or FELE or TMO?
Over the past 5 years, Franklin Electric Co.
, Inc. (FELE) delivered a total return of +21. 6%, compared to -23. 2% for Danaher Corporation (DHR). Over 10 years, the gap is even starker: FELE returned +229. 5% versus VLTO's +9. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VLTO or WAT or DHR or FELE or TMO?
By beta (market sensitivity over 5 years), Veralto Corporation (VLTO) is the lower-risk stock at 0.
61β versus Waters Corporation's 1. 11β — meaning WAT is approximately 82% more volatile than VLTO relative to the S&P 500. On balance sheet safety, Franklin Electric Co. , Inc. (FELE) carries a lower debt/equity ratio of 21% versus 86% for Veralto Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — VLTO or WAT or DHR or FELE or TMO?
By revenue growth (latest reported year), Waters Corporation (WAT) is pulling ahead at 7.
0% versus 2. 9% for Danaher Corporation (DHR). On earnings-per-share growth, the picture is similar: Veralto Corporation grew EPS 12. 6% year-over-year, compared to -15. 8% for Franklin Electric Co. , Inc.. Over a 3-year CAGR, VLTO leads at 4. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VLTO or WAT or DHR or FELE or TMO?
Waters Corporation (WAT) is the more profitable company, earning 20.
3% net margin versus 6. 9% for Franklin Electric Co. , Inc. — meaning it keeps 20. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: WAT leads at 28. 2% versus 12. 7% for FELE. At the gross margin level — before operating expenses — DHR leads at 60. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VLTO or WAT or DHR or FELE or TMO more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Franklin Electric Co. , Inc. (FELE) is the more undervalued stock at a PEG of 2. 48x versus Danaher Corporation's 33. 47x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 18. 7x forward P/E versus 24. 5x for Waters Corporation — 5. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DHR: 44. 3% to $247. 00.
08Which pays a better dividend — VLTO or WAT or DHR or FELE or TMO?
In this comparison, FELE (1.
1% yield), DHR (0. 7% yield), VLTO (0. 5% yield), TMO (0. 4% yield) pay a dividend. WAT does not pay a meaningful dividend and should not be held primarily for income.
09Is VLTO or WAT or DHR or FELE or TMO better for a retirement portfolio?
For long-horizon retirement investors, Veralto Corporation (VLTO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
61), 0. 5% yield). Both have compounded well over 10 years (VLTO: +9. 1%, WAT: +165. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VLTO and WAT and DHR and FELE and TMO?
These companies operate in different sectors (VLTO (Industrials) and WAT (Healthcare) and DHR (Healthcare) and FELE (Industrials) and TMO (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
VLTO, DHR, FELE pay a dividend while WAT, TMO do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.